Two weeks after going public, Jacksonville biopharmaceutical company Cadrenal Therapeutics Inc. celebrated its new listing by ringing the closing bell at the Nasdaq stock exchange.
Cadrenal is focused on developing tecarfarin, a drug that will be aims to prevent blood clots in people who have end-stage renal disease and atrial fibrillation, or irregular heart beats. The FDA considers tecarfarin an orphan drug, which means the company qualifies for certain tax credits and other incentives to help bring it to market. It has also received fast track designation, which speeds up the process of getting a drug approved.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Expansion Jacksonville soccer team selects former JU coach for leadership position - Jacksonville Business JournalMauricio Ruiz joined the organization in a business development role where he will also 'advise and support' operations.
더 많은 것을 읽으십시오 »
Jacksonville Airport construction - Jacksonville Business JournalJacksonville International has many changes in store to make travel more efficient for every passenger. See where all of the major projects stand today.
더 많은 것을 읽으십시오 »
Expansion Jacksonville soccer team selects former JU coach for leadership position - Jacksonville Business JournalMauricio Ruiz joined the organization in a business development role where he will also 'advise and support' operations.
더 많은 것을 읽으십시오 »
Concessions offered to lure office tenants are eating away at landlords' income - Jacksonville Business JournalA growing spread between starting and effective rents illustrates how office landlords — even among coveted Class A buildings — are seeing their rental income eroded as the office market remains squarely in favor of tenants.
더 많은 것을 읽으십시오 »